Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street ...

Amedisys (AMED) delivered earnings and revenue surprises of 10.62% and 0%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2025. Net service revenue increased ...

UnitedHealth, Amedisys and antitrust regulators will have a magistrate judge’s help in hashing out a solution to the DOJ’s ...

The U.S. Department of Justice’s (DOJ) lawsuit against Amedisys Inc. (NASDAQ: AMED) and UnitedHealth Group (NYSE: UNH) will ...

A federal judge in Maryland ordered the Justice Department and UnitedHealth Group to begin mediation on Aug. 18.

Amedisys had a net margin of 3.57% and a return on equity of 12.20%. Sell-side analysts expect that Amedisys will post 4.4 earnings per share for the current year. Hedge Funds Weigh In On Amedisys ...

RBC Capital analyst Ben Hendrix maintained a Buy rating on Amedisys (AMED – Research Report) yesterday and set a price target of $100.00.Stay ...

Highlights,Geode Capital Management increased its stake in Amedisys during the last quarter.,Major financial institutions have added or expanded positions in Amedisys.,The company posted steady ...